Go offline with the Player FM app!
Treating Metastatic Colorectal Cancer with KRAS Biomarker With Dr. Mark Erlander Cardiff Oncology
Manage episode 263383319 series 99915
Dr. Mark Erlander, CEO, Cardiff Oncology identifies the unmet needs of those suffering from metastatic colorectal cancer who have the oncogene KRAS mutation that hyper-drives the tumor growth. Mark talks about the company's investigational drug, onvansertib that is being evaluated in metastatic colorectal cancer (mCRC), acute myeloid leukemia (AML), and metastatic castrate-resistant prostate cancer (mCRPC). Onvansertib is a first-in-class, third-generation, oral and highly-selective inhibitor of PLK1, an enzyme that is over-expressed in most types of cancers. Onvansertib works synergistically in combination with approved chemotherapies and targeted therapeutics.
@CardiffOncology
#onvansertib #cancer #oncology #drugdevelopment #colorectalcancer #KRAS
1895 episodes
Manage episode 263383319 series 99915
Dr. Mark Erlander, CEO, Cardiff Oncology identifies the unmet needs of those suffering from metastatic colorectal cancer who have the oncogene KRAS mutation that hyper-drives the tumor growth. Mark talks about the company's investigational drug, onvansertib that is being evaluated in metastatic colorectal cancer (mCRC), acute myeloid leukemia (AML), and metastatic castrate-resistant prostate cancer (mCRPC). Onvansertib is a first-in-class, third-generation, oral and highly-selective inhibitor of PLK1, an enzyme that is over-expressed in most types of cancers. Onvansertib works synergistically in combination with approved chemotherapies and targeted therapeutics.
@CardiffOncology
#onvansertib #cancer #oncology #drugdevelopment #colorectalcancer #KRAS
1895 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.